Novo Nordisk revolutionary weight loss therapy CagriSema is coming! Can it reshape the market landscape?
Novo Nordisk is eager to prove the superiority of its new product Cagrilin peptide in a mixture with semaglutide before December, in order to maintain its leading position in the field of obesity treatment.
How Does Viking's Weight Loss Med Compare to Ones From Novo, Eli Lilly?
Viking Stock Drops 13% After Jumping 9% on Obesity Drug Data
New Study Reveals Another Benefit in Using Novo Nordisk's Wegovy in Obesity
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
Nvidia rises to the top again! Surpassing Apple to become the global market cap leader.
The global market cap leader changes hands again.